Pancreatitis inducida por mesalacina en pacientes con enfermedad inflamatoria intestinal

Abstract

Aminosalicylates are the drugs of first-choice in the management of patients with mild to moderate ulcerative colitis. In general they are safe and well-tolerated drugs. Nevertheless, cases have been described where a pancreatitis has developed as a possible complication of the treatment with aminosalicylates. It has been suggested that the mechanism these drugs use to induce inflammation on a pancreatic level is idiosyncratic. Conversely, even if cases of mesalazine-induced pancreatitis are usually mild, their recurrence rate is high, even when administered rectally. Therefore, a close monitoring must be carried out in the event that a patient who already suffered mesalazine-induced pancreatitis needs to be provided with the treatment again. We present the case of a patient with ulcerative colitis who developed a pancreatitis secondary to oral treatment with mesalazine; both the rectally administered mesalazine as well as a different formulation or oral mesalazine developed the recurrence of episodes of pancreatitis.